Login to Your Account



Search

Search results

Pharma: Clinic roundup

Eisai Inc. , of Woodcliff Lake, N.J., said it started a phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as first- or second-line treatment for HER2-negative locally recurrent or meta ...

BioWorld Today - Staff - 2014-02-28 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bristol-Myers Squibb Co. , of New York, and the Institute of Research in Immunology and Cancer in Montreal identified a molecule acting on a “novel therapeutic target” that was undisclosed. (BioWorld-Today-2014-02-27) ...

BioWorld Today - Staff - 2014-02-27 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Janssen Research & Development LLC , of Raritan, N.J., part of Johnson & Johnson, started the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) phase III, global, multicenter study of Invok ...

BioWorld Today - Staff - 2014-02-24 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bayer AG , of Leverkusen, Germany, said its Bayer Healthcare unit began enrolling patients in the phase III COAST trial of Stivarga (regorafenib) in colorectal cancer (CRC) patients with resected liver metastases. (BioWorld-Today-2014-02-21) ...

BioWorld Today - Staff - 2014-02-21 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eli Lilly and Co. , of Indianapolis, said the randomized, double-blind, global phase III REVEL study of ramucirumab in combination with chemotherapy in second-line non-small-cell lung cancer (NSCLC) showed a statistically significant improvement in t ...

BioWorld Today - Staff - 2014-02-20 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bayer Healthcare , of Whippany, N.J., reported positive results from the PROTECT VIII trial evaluating the company’s investigational long-acting site-specific pegylated recombinant human factor VIII compound BAY 94-9027. (BioWorld-Today-2014 ...

BioWorld Today - Staff - 2014-02-19 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Ipsen SA , of Paris, reported results of the international phase III clinical trial of Dysport Next Generation (DNG), an injectable form of botulinum toxin type A, in cervical dystonia. DNG was clinically and statistically superior to placebo in th ...

BioWorld Today - Staff - 2014-02-06 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, said the randomized Phase II (PALOMA-1) of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for the combination of pal ...

BioWorld Today - Staff - 2014-02-04 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line data from two Phase III studies of irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small-cell lung cancer (NSCLC), neither of which met their primary objectives. ...

BioWorld Today - Staff - 2014-01-28 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line results from a Phase III study of ALO-02 (oxycodone hydrochloride/naltrexone hydrochloride extended-release capsules) in patients with moderate to severe chronic low back pain, showing that the drug met th ...

BioWorld Today - Staff - 2014-01-24 00:00 - 0 comments - 0 attachments